Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial

by Cherney, David Z., Dekkers, Claire C. J., Barbour, Sean J., Cattran, Daniel, Gafor, Abdul Halim Abdul, Greasley, Peter J., Laverman, Gozewijn D., Lim, Soo Kun, Di Tanna, Gian Luca, Reich, Heather N., Vervloet, Marc G., Wong, Muh Geot, Gansevoort, Ron T., Heerspink, Hiddo J. L., Investigators, DIAMOND
Published 2020